China Biotech Gene Therapy: CRISPR Trials & $50B Market
China's biotech gene therapy sector has emerged as a global force, with over 50 CRISPR-based clinical trials underway and the world's second-largest CAR-T cell therapy market. Chinese biotech companies like BGI Genomics, BeiGene, and I-Mab are developing next-generation gene therapies for cancer, rare diseases, and genetic disorders. China's gene therapy market reached approximately $5 billion in 2025, growing at 35% annually toward a projected $50 billion by 2035. The government's 14th Five-Year Plan designated biotechnology as a strategic priority, allocating 200B RMB in research funding. Chinese scientists achieved breakthroughs in base editing and prime editing, publishing landmark papers in Nature and Science.
TL;DR
50+ CRISPR clinical trials active in China. CAR-T therapy market $2B+ with 6 approved products. Gene therapy market $5B growing 35% annually. BeiGene and BGI leading global biotech. 200B RMB government biotech funding.
Key Insights
CRISPR Clinical Trials
China has over 50 active CRISPR-based clinical trials, covering blood disorders (beta-thalassemia, sickle cell), cancers (leukemia, lymphoma), and hereditary diseases. Chinese researchers pioneered CRISPR-edited immune cell therapies, with several candidates in Phase 2/3 trials. Editas Medicine and CRISPR Therapeutics both established China partnerships for clinical development.
CAR-T Cell Therapy
China approved 6 CAR-T cell therapy products, more than any country except the US. Fosun Kite's Yescarta (axi-cel) and JW Therapeutics' Relma-cel treat lymphoma and leukemia. CAR-T therapy costs approximately 300,000 RMB in China, 80% cheaper than US pricing. Over 5,000 Chinese patients received CAR-T treatment by 2025.
BeiGene Global Expansion
BeiGene became China's largest biotech company with over $3 billion annual revenue, driven by its Brukinsa (zanubrutinib) blood cancer drug approved in 70+ countries. Brukinsa competes directly with AbbVie's Imbruvica and achieved $2.5 billion global sales. BeiGene invested $2B in R&D with 10,000+ employees across 45 countries.
Base Editing Breakthroughs
Chinese researchers launched the world's first prime editing clinical trials for genetic liver disease. Base editing technology from Chinese startups achieved 95%+ correction efficiency for sickle cell mutations in lab studies. Shanghai-based Beam Therapeutics China advanced several base editing programs for blood disorders into clinical trials.
Side-by-Side Comparison
| Gene Therapy Type | Clinical Trials (China) | Products Approved | Key Companies | Target Diseases |
|---|---|---|---|---|
| CAR-T Cell Therapy | 100+ | 6 products | JW Therapeutics, Fosun Kite, Legend Biotech | Leukemia, Lymphoma |
| CRISPR Gene Editing | 50+ | 0 (in trials) | Editas China, CRISPR Therapeutics JV, GenEdit | Blood disorders, Cancer |
| Base/Prime Editing | 20+ | 0 (in trials) | Beam Therapeutics China, Prime Medicine JV | Liver disease, Sickle cell |
| AAV Gene Therapy | 30+ | 0 (in trials) | Huida Gene, BrainStorm China | Hemophilia, Blindness |
| RNA Therapy | 40+ | 2 approved | Suzhou Abogen, Sirnaomics | COVID, Cancer, Rare disease |
| mRNA Platform | 50+ | 3 approved (COVID) | Abogen Biosciences, StemiRNA | COVID, Cancer vaccines |
| CAR-NK Cell Therapy | 15+ | 0 (in trials) | Chimeric Therapeutics, Nkarta China | Solid tumors |
| Stem Cell Therapy | 100+ | 5 approved | Beike Biotech, BGI | Spinal cord, Heart disease |
Frequently Asked Questions
China's gene therapy sector is rapidly closing the gap with the US and leading in some areas: CAR-T therapy, China has 6 approved CAR-T products compared to 6 in the US, but Chinese pricing at approximately 300,000 RMB versus $373,000 USD in the US makes treatment more accessible, and China leads in total number of CAR-T clinical trials with over 100 active trials; CRISPR clinical trials, China has approximately 50 CRISPR trials compared to approximately 80 in the US, but China leads in certain areas like CRISPR-edited cell therapy for blood disorders and cancer; regulatory pathway, China's NMPA has accelerated gene therapy approvals through breakthrough therapy designation, with average review times dropping from 18 months to 12 months, comparable to FDA's accelerated pathways; manufacturing, China lags in viral vector manufacturing capacity with approximately 5 GMP facilities versus 20+ in the US, but is investing aggressively with 10 new facilities under construction; and global competitiveness, BeiGene is the only Chinese biotech company achieving blockbuster drug status globally with Brukinsa, while most Chinese gene therapy companies remain domestically focused. China's main advantages are lower clinical trial costs (40% cheaper), faster patient recruitment, and large patient populations for rare diseases.